Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus

Pharmacotherapy
Curtis TriplittElaine Chiquette

Abstract

The emergence of the glucoregulatory hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide has expanded our understanding of glucose homeostasis. In particular, the glucoregulatory actions of the incretin hormone GLP-1 include enhancement of glucosedependent insulin secretion, suppression of inappropriately elevated glucagon secretion, slowing of gastric emptying, and reduction of food intake. Two approaches have been developed to overcome rapid degradation of GLP-1. One is the use of agents that mimic the enhancement of glucose-dependent insulin secretion, and potentially other antihyperglycemic actions of incretins, and the other is the use of dipeptidyl peptidase-IV inhibitors, which reduce the inactivation of GLP-1, increasing the concentration of endogenous GLP-1. The development of incretin mimetics and dipeptidyl peptidase-IV inhibitors opens the door to a new generation of antihyperglycemic agents to treat several otherwise unaddressed pathophysiologic defects of type 2 diabetes mellitus. We review the physiology of glucose homeostasis, emphasizing the role of GLP-1, the pathophysiology of type 2 diabetes mellitus, the clinical shortcomings of current therapies, and the potential of n...Continue Reading

References

May 1, 1992·Molecular and Cellular Endocrinology·H C FehmannB Göke
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D J DruckerJ F Habener
Oct 1, 1987·The Journal of Clinical Investigation·L RossettiR A DeFronzo
Jan 1, 1986·Diabetologia·M NauckW Creutzfeldt
Jun 1, 1969·The American Journal of the Medical Sciences·E Aguilar-ParadaR H Unger
Jul 16, 1970·The New England Journal of Medicine·W A MüllerR H Unger
Apr 1, 1970·The Journal of Clinical Investigation·R H UngerA M Eisentraut
Aug 19, 1971·The New England Journal of Medicine·R H Unger
Dec 1, 1967·The Journal of Clinical Investigation·M J Perley, D M Kipnis
Jun 18, 1981·The New England Journal of Medicine·R H Unger, L Orci
Feb 1, 1995·Acta Physiologica Scandinavica·B Ahrén
Jun 1, 1994·Diabetologia·M Horowitz, R Fraser
Dec 1, 1994·Digestive Diseases and Sciences·M HorowitzG Hebbard
May 1, 1996·Diabetes Care·J G SchwartzW T Phillips
Oct 22, 1998·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·B Ahrén
Feb 9, 2000·Life Sciences·R G Yip, M M Wolfe
Jul 6, 2000·Annals of Internal Medicine·R A DeFronzo
Dec 22, 2000·European Journal of Endocrinology·R Perfetti, P Merkel
Oct 13, 2001·The Journal of Biological Chemistry·Y KashimaS Seino
Sep 10, 2002·American Journal of Physiology. Endocrinology and Metabolism·Bidda RolinLotte Bjerre Knudsen
Jul 5, 2003·The Journal of Clinical Endocrinology and Metabolism·Orville G KoltermanAlain D Baron
Sep 17, 2003·Current Diabetes Reports·Bo Ahrén
Sep 30, 2003·Diabetes Care·Daniel J Drucker
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Sharon H SaydahCatherine C Cowie

❮ Previous
Next ❯

Citations

Aug 7, 2007·Journal of Molecular Modeling·Raghuvir R S PissurlenkarEvans C Coutinho
Jan 4, 2007·The Journal of Clinical Investigation·Juanita L Merchant
Dec 19, 2008·Pediatric Research·Vandana S Raman, Rubina A Heptulla
Sep 15, 2009·Drugs·Katherine F Croom, Paul L McCormack
Apr 28, 2007·Bioorganic & Medicinal Chemistry Letters·Nam Sook KangSung-Eun Yoo
Dec 10, 2013·The Open Medicinal Chemistry Journal·Víctor H Vázquez-ValadezEnrique Angeles
Apr 14, 2015·The Open AIDS Journal·Daniel B ChastainKayla R Stover
Jun 20, 2018·Obesity Surgery·Miguel F HerreraJuan Antonio López Corvalá
Mar 1, 2007·Expert Review of Endocrinology & Metabolism·Franziska Philomena Busse, Michael Stumvoll
Aug 25, 2021·Bioorganic & Medicinal Chemistry·Shubham KumarAmit Mittal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.